Evidence map›Paper›PMID 42367755›Full record

ArticleFrontiers in immunology2026

Case Report: Bilateral optic nerve head masses and retinopathy in a patient with B-cell acute lymphoblastic leukemia receiving CAR T-cell therapy masquerading as fungal endophthalmitis.

Jacob S Heng, Eugenia Ramos-Davila, Alejandra M Maiz, Amanda Henderson, Charles G Eberhart, Paulina Liberman, Jean-Yves Métais, Stephen Gottschalk, Kristen E Schratz, Heather Symons and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jacob S HengRetina Division, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, United States.
Eugenia Ramos-DavilaDivision of Ocular Immunology, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, United States.
Alejandra M MaizRetina Division, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, United States.
Amanda HendersonNeuro-ophthalmology Division, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, United States.
Charles G EberhartOcular Pathology, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, United States.
Paulina LibermanDivision of Ocular Immunology, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, United States.
Jean-Yves MétaisDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, United States.
Stephen GottschalkDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, United States.
Kristen E SchratzDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Heather SymonsDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Challice L BonifantDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
James T HandaRetina Division, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cells can traffic across tissue planes and thus have considerable potential to clear disease in sanctuary sites inaccessible to alternate systemic treatments. While of great clinical benefit, this unique capability is associated with distinctive potential toxicity. Tumor inflammation-associated neurotoxicity (TIAN) is characterized by local inflammatory toxicity at tumor sites within the CNS, presumably initiated by CAR T cells penetrating the blood-brain barrier (BBB). Specifically, ocular toxicity of CAR T-cell treatment affecting the retina and optic nerve may represent a variant of TIAN and has been infrequently described. We highlight a unique case of bilateral optic nerve head masses and retinopathy masquerading as fungal endophthalmitis in a patient with B-cell ALL treated with CAR T-cell therapy. With early recognition and a multidisciplinary approach, such cases of ocular TIAN can be effectively managed.

Indexed as

EndophthalmitisEye Infections, FungalImmunotherapy, AdoptiveOptic DiskPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRetinal DiseasesDiagnosis, DifferentialHumansReceptors, Chimeric AntigenReceptors, Chimeric AntigenCAR-T cell therapyocular adverse eventoptic nerve abnormalitiesoptic neuropathyretinopathytisagenlecleuceltumor inflammationvitreal floaters

Identifiers

PMID42367755
PMCPMC13294182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.